Free Trial

Judge outlines holes in DOJ suit to stop UnitedHealth deal

A sign stands on UnitedHealth Group Inc.'s campus in Minnetonka, Minn., on Oct. 16, 2012. Federal regulators failed to show that UnitedHealth Group’s purchase of technology company Change Healthcare will likely hurt competition, a judge explained in a memo Wednesday, Sept. 22, 2022. (AP Photo/Jim Mone, File)

Federal regulators failed to show that UnitedHealth Group’s purchase of technology company Change Healthcare will likely hurt competition, a judge explained in a memo outlining his rejection of a lawsuit over the deal.

The U.S. Department of Justice had sued in February to block the roughly $8 billion acquisition, with regulators noting at the time that they feared it would put too much health care claims information in the hands of one company.

But U.S. District Judge Carl Nichols Issued an order earlier this week denying the government’s request to end the deal. The case had been the subject of a trial in August.

UnitedHealth Group runs the nation’s largest health insurer and operates rapidly growing businesses that process pharmacy claims and deliver care.

Justice department officials said in February that the deal would give UnitedHealth control of a “critical data highway through which about half of all Americans’ health insurance claims pass each year.”

They added that the company could then use that sensitive information from rivals for its own business purposes.

Nichols noted in a 58-page memorandum filed Wednesday that UnitedHealth’s incentives to protect customer data as it grows its businesses outweighs motivations to misuse the information.

The judge also noted that UnitedHealth has agreed to sell part of Change’s business to a private equity firm that will then invest in it, and that will likely preserve competition.

Assistant Attorney General Jonathan Kanter said in a statement Monday that the Justice Department was reviewing options for next steps and that they “respectfully disagree” with the decision.

Should You Invest $1,000 in UnitedHealth Group Right Now?

Before you consider UnitedHealth Group, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and UnitedHealth Group wasn't on the list.

While UnitedHealth Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
UnitedHealth Group (UNH)
4.9493 of 5 stars
$336.720.6%2.63%14.59Moderate Buy$358.95
Compare These Stocks  Add These Stocks to My Watchlist 

Featured Articles and Offers

Recent Videos

Robot Revolution: 3 Must-Know Plays for Investors
Fed Decision Day  — What Today’s Move Means for Stocks
The AI-Proof Portfolio: 3 Stocks You Need to See

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines